Arvinas (ARVN) Share-based Compensation Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Share-based Compensation Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -7.69% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | -8.89% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -22.43% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -4.01% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | -42.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.72% |
| Mar 31, 2026 | -19.33% |
| Dec 31, 2025 | -63.52% |
| Sep 30, 2025 | -58.70% |
| Jun 30, 2025 | -52.31% |
| Mar 31, 2025 | -19.35% |
| Dec 31, 2024 | 39.52% |
| Sep 30, 2024 | 47.90% |
| Jun 30, 2024 | 18.03% |
| Mar 31, 2024 | -6.53% |
| Dec 31, 2023 | -16.92% |
| Sep 30, 2023 | -11.17% |
| Jun 30, 2023 | -8.50% |
| Mar 31, 2023 | 19.88% |
| Dec 31, 2022 | 18.24% |
| Sep 30, 2022 | 23.48% |
| Jun 30, 2022 | 268.13% |
| Mar 31, 2022 | 61.17% |
| Dec 31, 2021 | 110.44% |
| Sep 30, 2021 | 84.61% |